日本臨牀　75/増刊8　がん転移学（上）

出版社： 日本臨牀社
発行日： 2017-11-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： がん転移学（上）―がん転移のメカニズムと治療戦略：その基礎と臨床―
電子書籍版： 2017-11-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

9,900 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

9,900 円(税込)

購入する

目次

  • 特集　がん転移学（上）―がん転移のメカニズムと治療戦略：その基礎と臨床―

    I．総　論
    　１．がん転移の基礎研究の歴史と展望
    ２．がん転移の臨床研究の歴史と展望

    II．がんの疫学
    　１．がん転移の疫学と動向-がん登録データに垣間見る日本のがん診断と治療の進歩
    　２．臓器別のがん転移に関する疫学情報
    　（１）食道がん
    　（２）肺がん
    　（３）乳がん
    　（４）胃がん
    　（５）がん登録データからみた大腸がん転移の疫学
    　（６）肝がんの転移の疫学
    　（７）膵がん
    　（８）前立腺がん
    　（９）子宮頸がんと子宮体がん
    　３．がんのリスク・予防要因―世界と日本
    　４．日本人大規模コホート研究からみた生活習慣とがんリスク
    　５．アジアコホートコンソーシアム研究からみた生活習慣とがんリスク
    　６．国際コホートコンソーシアム研究からみた生活習慣とがんリスク
    　７．放射線被ばくによるがんリスク
    　８．ゲノム・遺伝子情報を用いたがんの疫学研究
    　９．大腸がん化学予防介入試験―アスピリンを中心に
    　11．前立腺がん化学予防の現状

    III．がん転移学の基礎研究
    　１．がんの浸潤と転移のメカニズム
    　２．in vivo 選択法による高転移がん細胞亜株の分離
    　３．がん幹細胞とエピゲノム制御
    　４．がん転移における細胞接着分子の異常
    　５．がん転移を制御する腫瘍微小環境
    　６．がんの発生進展の分子機構
    　（１）頭頸部癌の分子機構
    　（２）非小細胞肺癌の分子機構
    　（３）食道癌の分子機構
    　（４）胃癌の分子機構
    　（５）大腸癌の分子機構
    　（６）肝癌の分子機構
    　（７）胆道癌の分子機構
    　（８）がん細胞の上皮可塑性と間質相互作用による膵がん進展機構
    　（９）腎癌の分子生物学と発癌機序
    （10）浸潤性膀胱癌の分子機構
    （11）前立腺癌の分子機構
    （12）精巣癌の分子機構
    （13）子宮頸癌の分子機構
    （14）子宮体癌の分子機構
    （15）卵巣癌の分子機構
    （16）乳癌の分子機構
    （17）皮膚悪性黒色腫の分子機構
    （18）中枢神経系腫瘍の分子機構

    IV．がん転移の臨床（研究）
    　1．転移がんの診断
    （１）転移がんの画像診断（CT、MRIを中心に）
    （２）転移がんの核医学画像診断：SPECTとPET
    　（３）転移の分子診断
    　２．転移がんの治療
    　（１）がん転移に対する外科療法
    　（２）放射線治療概論
    　（３）薬物療法総論
    　３．緩和医療概論

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.5 掲載の参考文献
1) がん統計 '16. [http://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2016_jp.html] (2017年9月閲覧)
 
2) Amir E, et al : Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol 29 : 2543-2549, 2011.
PubMed
3) Scannell JW, et al : Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11 : 191-200, 2012.
 

I 総論

P.14 掲載の参考文献
1) Paget S : The distribution of secondary growths in cancer of the breast. Lancet 133 : 571-573, 1889.
 
2) Ewing J : Neoplastic Diseases : A Treatise on Tumors, 3rd edition, p293, WB Saunders, Philadelphia, 1928.
 
3) Fidler IJ : Selection of successive tumour lines for metastasis. Nature New Biol 242 : 148-149, 1973.
PubMed
4) Liotta LA : Tumor invasion and metastases--role of the extracellular matrix : Rhoads Memorial Award lecture. Cancer Res 46 : 1-7, 1986.
PubMed
5) Fidler IJ : Metastasis : quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 45 : 773-782, 1970.
 
6) Kreso A, Dick JE : Evolution of the cancer stem cell model. Cell Stem Cell 14 : 275-291, 2014.
PubMed
7) Nieto MA, et al : EMT : 2016. Cell 166 : 21-45, 2016.
PubMed
8) Lambert AW, et al : Emerging Biological Principles of Metastasis. Cell 168 : 670-691, 2017.
PubMed
9) Zheng X, et al : Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527 : 525-530, 2015.
PubMed
10) Krebs AM, et al : The EMT-activator Zebl is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol 19 : 518-529, 2017.
 
11) Mani SA, et al : The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 : 704-715, 2008.
PubMed
12) Fidler IJ : Macrophages and metastasis-a biological approach to cancer therapy. Cancer Res 45 : 4714-4726, 1985.
PubMed
13) Weidner N, et al : Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 : 1-8, 1991.
PubMed
14) Kalluri R : The biology and function of fibroblasts in cancer. Nat Rev Cancer 16 : 582-598, 2016.
PubMed
15) Peinado H, et a1 : Pre-metastatic niches : organ-specific homes for metastases. Nat Rev Cancer 17 : 302-317, 2017.
 
P.20 掲載の参考文献
1) Kohno N, et al : Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer : arandomized, placebo-controlled trial. J Clin Oncol 23 : 3314-3321, 2005.
 
2) Saad F, et al : A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 94 : 1458-1468, 2002.
 
3) Rosen LS, et al : Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors : a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21 : 3150-3157, 2003.
 
4) Stopeck AT, et al : Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized, double-blind study. J Clin Oncol 28 : 5132-5139, 2010.
PubMed
5) Fizazi K, et al : Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet 377 : 813-822, 2011.
PubMed
6) Henry DH, et al : Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29 : 1125-1132, 2011.
PubMed
7) Lipton A, et al : Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : a combined analysis of 3 pivotaL randomised, phase 3 trials. Eur J Cancer 48 : 3082-3092, 2012.
PubMed
8) Overall CM, et al : Tumour microenvironment-opinion : validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6 : 227-239, 2006.
 
9) Shepherd FA, et al : Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer : a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20 : 4434-4439, 2002.
 
10) Hirte H, et al : A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy : a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 102 : 300-308, 2006.
 
11) Fujiwara Y, et al : Phase 1 study of galunisertib, a TGF-beta receptor 1 kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 76 : 1143-1152, 2015.
PubMed
12) Finn RS, et al : The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18) : a randomised phase 2 study. Lancet Oncol 16 : 25-35, 2015.
PubMed
13) Stupp R, et al : Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15 : 1100-1108, 2014.
PubMed
14) Shitara K, et al : Dose-escalation study for the targeting of CD44v (+) cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). Gastric Cancer 20 : 341-349, 2017.
PubMed
15) Nojiri T, et al : Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells. Proc Natl Acad Sci USA 112 : 4086-4091, 2015.
PubMed

II がんの疫学

P.30 掲載の参考文献
1) Robinson JR, et al : Stage IV colorectal cancer primary site and patterns of distant metastasis. Cancer Epidemiol 48 : 92-95, 2017.
PubMed
3) 松田智大 : 日本のがん対策の新しい動き 科学的根拠に基づいたがん対策を進めるために 全国がん登録の開始に向けて. 癌の臨床 60 : 567-574, 2014.
 
4) Okamoto N : Ahistory of the cancer registration system in Japan. Int J Clin Oncol 13 : 90-96, 2008.
 
5) がん登録等の推進に関する法律, 平成25年法律第111号, 2013.
 
6) Cancer IAfRo, Registries IAoC. Cancer Registration : Principles and Methods, Internatioonal Agency for Research on Cancer, Lyon, 1991.
 
7) 松田智大, ほか : 全国がん罹患モニタリング集計 2012年罹患数・率報告, 国立がん研究センターがん対策情報センター, 2016.
 
8) 片野田耕太 : 背景と方法. JACR Monograph (Suppl 2) : 1-5, 2016.
 
9) Yu JB, et al : NCI SEER public-use data : applications and limitations in oncology research. Oncology (Williston Park) 23 : 288-295, 2009.
PubMed
10) Kamo K, et al : A mathematical estimation of true cancer incidence using data from population-based cancer registries. Jpn J Clin Oncol 37 : 150-155, 2007.
PubMed
11) 国立がん研究センター社会と健康研究センター検診研究部検診評価研究室 : がん検診ガイドライン 推奨のまとめ 2014. [http://canscreen.ncc.go.jp/guideline/matome.html] (2017年9月閲覧)
 
2）Stalberg K, et al : Risk factors for lymph node metastases in women with endometrial cancer : A population-based, nation-wide register study-On behalf of the Swedish Gynecological Cancer Group. Int J Cancer 140 : 2693-2700, 2017.
 
P.34 掲載の参考文献
1) 西本寛, ほか : 全国がん罹患モニタリング集計 2012年罹患数・率報告, 国立研究開発法人国立がん研究センターがん対策情報センター, 2016.
 
2) 大臣官房統計情報部人口動態・保健社会統計課 : 人口動態統計年報, 厚生労働省, 2015.
 
3) Tachimori Y, et al : Comprehensive Registry of Esophageal Cancer in Japan, 2010. Esophagus 14 : 189-214, 2017.
PubMed
4) 西本寛, ほか : 全国がん罹患モニタリング集計 2006-2008年生存率報告, 国立研究開発法人国立がん研究センターがん対策情報センター, 2016.
 
5) 食道癌診断・治療ガイドライン 2012年4月版 (日本食道学会編), 金原出版, 2012.
 
P.40 掲載の参考文献
1) 西本寛, ほか : 全国がん罹患モニタリング集計 2012年罹患数・率報告, 国立研究開発法人国立がん研究センターがん対策情報センター, 2016.
 
2) 大臣官房統計情報部人口動態・保健社会統計課 : 人口動態統計年報, 厚生労働省, 2015.
 
3) 国立がん研究センター社会と健康研究センター. 科学的根拠に基づく発がん性・がん予防効果の評価とがん予防ガイドライン提言に関する研究 [http://epi.ncc.go.jp/can_prev/index.html] (2017年10月閲覧)
 
4) Inoue M, et al : Attributable causes of cancer in Japan in 2005-systematic assessment to estimate current burden of cancer attributable to known preventable risk factors in Japan. Ann Oncol 23 : 1362-1369, 2012.
PubMed
5) Quint LE, et al : Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 62 : 246-250, 1996.
PubMed
6) 西本寛, ほか : がん診療連携拠点病院 院内がん登録 2014年全国集計報告書, 国立研究開発法人国立がん研究センターがん対策情報センター, 2016.
 
7) 祖父江友孝 : 肺がん. JACR Monograph (Suppl 2) : 63-73, 2016.
 
8) 公益財団法人健康・体力づくり事業財団. 厚生労働省の最新たばこ情報 [http://www.health-net.or.jp/tobacco/front.html] (2017年10月閲覧)
 
9) Ito H, et al : Nonfilter and filter cigarette consumption and the incidence of lung cancer by histological type in Japan and the United States : analysis of 30-year data from population-based cancer registries. Int J Cancer 128 : 1918-1928, 2011.
PubMed
10) 厚生労働省 : 地域保健・健康増進事業報告 [http://www.mhlw.go.jp/toukei/list/32-19.html] (2017年10月閲覧)
 
P.44 掲載の参考文献
1) 西本寛, ほか : 全国がん罹患モニタリング集計 2012年罹患数・率報告, 国立研究開発法人国立がん研究センターがん対策情報センター, 2016.
 
2) 一般財団法人厚生労働統計協会 : 国民衛生の動向 6 : 63-67, 2016.
 
3) National Cancer Institute : SEER SUMMARY STAGING MANUAL-2000 CODES AND CODING INSTRUCTIONS, 2000. [https://seer.cancer.gov/tools/ssm/intro.pdf] (2017年9月閲覧)
 
4) 地域がん登録の手引き改訂第5版2013年版, 26, 特定非営利活動法人地域がん登録全国協議会, 2013.
 
5) World Cancer Research Fund International : Continuous Update Project findings & reports, 2017. [http://www.wcrf.org/int/research-we-fund/continuous-update-project-findings-reports/breast-cancer] (2017年9月閲覧)
 
6) 国立がん研究センター : 科学的根拠に基づく発がん性・がん予防効果の評価とがん予防ガイドライン提言に関する研究 [http://epi.ncc.go.jp/cgi-bin/cms/public/index.cgi/nccepi/can_prev/outcome/index] (2017年9月閲覧)
 
7) 国立がん研究センター : がん情報サービス. [http://ganjoho.jp/reg_stat/can_reg/national/about.html] (2017年9月閲覧)
 
8) 金村政輝, 辻一郎 : 全国がん登録の開始と院内がん登録の新しい展開, 医学のあゆみ 256 : 169-170, 2016.
Medical*Online
9) Mariotto AB, et al : Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. Cancer Epidemiol Biomarkers Prev 26 : 809-815, 2017.
PubMed
10) 一般社団法人日本乳がん学会. [http://jbcs.gr.jp/member/iinkaiyori/touroku/] (2017年9月閲覧)
 
P.50 掲載の参考文献
1) 厚生労働省人口動態・保健社会統計室 : 人口動態統計特殊報告. [http://www.e-stat.go.jp/SG1/estat/GL02020101.do?method=csvDownload&fileld=000006596486&releaseCount=2] (2017年9月閲覧)
 
2) 西本寛, ほか (編) : 全国がん罹患モニタリング集計 2013年罹患数・率報告, p60, 国立がん研究センターがん対策情報センター, 2017.
 
3) 厚生労働省人口動態・保健社会統計室 : 人口動態調査. [http://www.e-stat.go.jp/SGI/estat/GLO8020103.do?_csvDownload_&fileId=000007806056&releaseCount=2] (2017年9月閲覧)
 
4) 国立がん研究センター社会と健康研究センター : 科学的根拠に基づく発がん性・がん予防効果の評価とがん予防ガイドライン提言に関する研究. [http://epi.ncc.go.jp/can_prev/index.html] (2017年9月閲覧)
 
5) 国立がん研究センターがん情報サービス がん登録・統計 グラフデータベース. [http://gdb.ganjoho.jp/graph_db/gdb5] (2017年9月閲覧)
 
6) Mizoue T, et al : Prospective study of screening for stomach cancer in Japan. Int J Cancer 106 : 103-107, 2003.
PubMed
7) Miyamoto A, et al : Lower risk of death from gastric cancer among participants of gastric cancer screening in Japan : a population-based cohort study. Prev Med 44 : 12-19, 2007.
PubMed
8) 祖父江友孝, ほか : 有効性評価に基づく胃がん検診ガイドライン 2014年度版, p1, 国立がん研究センターがん予防・検診研究センター, 2014. [http://canscreen.ncc.go.jp/pdf/iganguide2014_150421.pdf] (2017年9月閲覧)
 
9) Cho B, ほか : 学術研究サービス課題 最終結果報告書「現行の国家健康検診プログラム全般に対する妥当性の評価および制度改善方案の提示-検診対象, 検診間隔, 標的疾患, 検査項目, 費用効果などを中心に-」, ソウル大学医科大学, 2013.
 
P.56 掲載の参考文献
1) 西本寛, ほか : 全国がん罹患モニタリング集計 2012年罹患数・率報告, 国立研究開発法人国立がん研究センターがん対策情報センター, 2016.
 
2) 大臣官房統計情報部人口動態・保健社会統計課 : 人口動態統計年報, 厚生労働省, 2015.
 
3) 三原修一, ほか : 人間ドックにおけるがん登録-2011年度の成績 人間ドック 31 : 55-66, 2016.
Medical*Online
4) Arnold M, et al : Global patterns and trends in colorectal cancer incidence and mortality. Gut 66 : 683-691, 2017.
PubMed
5) Nakagawa H, et al : Changes in trends in colorectal cancer incidence rate by anatomic site between 1978 and 2004 in Japan. Eur J Cancer Prev 26 : 269-276, 2017.
PubMed
P.61 掲載の参考文献
1) 田中純子 : 厚生労働省肝炎等克服政策研究事業「急性感染も含めた肝炎ウイルス感染状況・長期経過と治療導入対策に関する研究」平成25年度研究成果報告書, 2014.
 
2) Uchino K, et al : Hepatocellular carcinoma with extrahepatic metastasis : clinical features and prognostic factors. Cancer 117 : 4475-4483, 2011.
PubMed
3) 工藤正俊, ほか : 第19回全国原発性肝癌追跡調査報告 (2006～2007). 肝臓 57 : 45-73, 2016.
 
4) 全国がん罹患モニタリング集計 : 2006-2008年厚生労働科学研究費補助金 (がん対策推進総合研究事業), 2016.
 
5) 国立がん研究センター : がん情報サービス. [http://ganjoho.jp/public/index.html] (2017年10月閲覧)
 
6) 近藤敏, ほか : 若年者肝細胞癌症例の検討. 日本消化器外科学会雑誌 24 : 1196-1200, 1991.
 
7) 田中照二, ほか : B型原発性肝細胞癌の臨床統計学的研究. 日本臨牀 53 (増刊) : 680-686, 1995.
 
8) 高後裕ほか : 我が国における非B非C肝硬変の実態調査 2011, 響文社, 2012.
 
9) Hashimoto E, et al : The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 33 : 72-76, 2005.
PubMed
10) 大山淳史, ほか : 非B非C肝癌の早期発見における肝臓専門医フォローアップの重要性. 肝臓 55 : 284-286, 2014.
 
P.66 掲載の参考文献
1) 最新がん統計, 国立がん研究センターがん情報サービス. [http://ganjoho.jp/reg_stat/statistics/stat/summary.html] (2017年9月閲覧)
 
2) 西本寛, ほか : 全国がん罹患モニタリング集計 2012年罹患数・率報告, 国立研究開発法人国立がん研究センターがん対策情報センター, 2016.
 
3) Matsuo K, et al : Cigarette smoking and pancreas cancer risk : an evaluation based on a systematic review of epidemiologic evidence in the Japanese population. Jpn J Clin Oncol 41 : 1292-1302, 2011.
PubMed
4) 国立研究開発法人国立がん研究センター社会と健康研究センター. 科学的根拠に基づく発がん性・がん予防効果の評価とがん予防ガイドライン提言に関する研究. [http://epi.ncc.go.jp/can_prev/index.html] (2017年9月閲覧)
 
5) がん診療連携拠点病院等院内がん登録全国集計. [http://ganjoho.jp/reg_stat/statistics/brochure/hosp_c_registry.html] (2017年9月閲覧)
 
6) 膵癌登録報告 2007. [https://www.jstage.jst.gojp/browse/suizo/22/1/_contents/-char/ja/] (2017年9月閲覧)
 
7) Oweira H, et al : Prognostic value of site-specific metastases in pancreatic adenocarcinoma : A Surveillance Epidemiology and End Results database analysis. World J Gastroenterol 23 : 1872-1880, 2017.
PubMed
8) Klein AP, et al : An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS ONE 8 : e72311, 2013.
PubMed
9) Song S, et al : Long-term diabetes mellitus is associated with an increased risk of pancreatic cancer : a meta-analysis. PLoS ONE 10 : e0134321, 2015.
PubMed
10) Risch HA : Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst 95 : 948-960, 2003.
 
11) 古瀬純司 : 膵癌化学療法のup to date. 日本消化器病学会雑誌 114 : 637-643, 2017.
Medical*Online
P.71 掲載の参考文献
1) 西本寛, ほか : 全国がん罹患モニタリング集計 2012年罹患数・率報告, 国立研究開発法人国立がん研究センターがん対策情報センター, 2016.
 
2) 大臣官房統計情報部人口動態・保健社会統計課 : 人口動態統計年報, 厚生労働省, 2015.
 
3) 国立研究開発法人国立がん研究センター社会と健康研究センター : 科学的根拠に基づく発がん性・がん予防効果の評価とがん予防ガイドライン提言に関する研究 [http://epi.ncc.go.jp/can_prev/index.html] (2017年9月閲覧)
 
4) 全国がん罹患モニタリング集計 2006-2008年生存率報告 (国立研究開発法人国立がん研究センターがん対策情報センター, 2016), 独立行政法人国立がん研究センターがん研究開発費「地域がん登録精度向上と活用に関する研究」平成22年度報告書.
 
5) Kenneth L, et al : Prostate-Specific Antigen-Based Screening for Prostate Cancer : An Evidence Update for the US. Preventive Services Task Force. Agency for Healthcare Research and Quality, 2011.
 
6) Qaseem A, et al : Screening for prostate cancer : a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 158 : 761-769, 2013.
PubMed
P.77 掲載の参考文献
1) 国立がん研究センターがん情報サービス「がん登録・統計」, がん統計,部位別がんの統計情報. [http://ganjoho.jp/reg_stat/statistics/stat/summary.html] (2017年9月閲覧)
 
2) 西本寛, ほか : 全国がん罹患モニタリング集計 2012年罹患数・率報告, 国立研究開発法人国立がん研究センターがん対策情報センター, 2016.
 
3) 大臣官房統計情報部人口動態・保健社会統計課 : 人口動態統計年報. 厚生労働省, 2015.
 
4) Moscicki AB, et al : Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 364 : 1678-1683, 2004.
PubMed
5) 笹川寿之 : ヒトパピローマウイルス (HPV) 感染と子宮頸癌-現状と対策. 臨床と微生物 34 : 363-371, 2007.
Medical*Online
6) 竹本周二, 嘉村敏治 : 婦人科がん-概論-自然史・疫学・統計. 日本臨牀 (増刊 : 婦人科がん) 70 : 5-9, 2012.
 
7) 国立研究開発法人国立がん研究センター社会と健康研究センター. 科学的根拠に基づく発がん性・がん予防効果の評価とがん予防ガイドライン提言に関する研究. [http://epi.ncc.go.jp/can_prev/index.html] (2017年9月閲覧)
 
8) Centers for Disease Control and Prevention, National Breast and Cervical Cancer Early Detection Program. [https://www.cdc.gov/cancer/nbccedp/about.htm] (2017年9月閲覧)
 
9) Siegl EJ, et al : Quality assurance through quality improvement and professional development in the National Breast and Cervical Cancer Early Detection Program. Cancer 120 (Suppl 16) : 2584-2590, 2014.
 
10) 厚生労働省統計, 地域保健・健康増進事業報告. [http://www.e-stat.go.jp/SGI/estat/GLO8020101.do?_toGLO802010L&tstatCode=000001030884&requestSender=dsearch] (2017年9月閲覧)
 
11) 国立がん研究センターがん情報サービス「がん登録・統計」, がん統計, がん検診受診率. [http://ganjoho.jp/reg_stat/statistics/stat/screening.html] (2017年9月閲覧)
 
12) 坂本尚徳. 深澤一夫 : 子宮頸がん子宮頸癌の進行期分類と治療方針. 日本臨牀 (増刊 : 婦人科がん) 70 : 128-132, 2012.
 
P.83 掲載の参考文献
1) Inoue M, et al : Attributable causes of cancer in Japan in 2005--systematic assessment to estimate current burden of cancer attributable to known preventable risk factors in Japan. Ann Oncol 23 : 1362-1369, 2012.
PubMed
2) 「科学的根拠に基づく発がん性・がん予防効果の評価とがん予防ガイドライン提言に関する研究」研究班HP. [http://epi.ncc.go.jp/can_prev/] (2017年9月閲覧)
 
3) Sasazuki S, et al : Combined impact of five Iifestyle factors and subsequent risk of cancer : the Japan Public Health Center Study. Prev Med 54 : 112-116, 2012.
 
4) 国立がん研究センター社会と健康研究センター予防研究グループ : がんリスクチェック [https://epi.ncc.go.jp/riskcheck/] (2017年9月閲覧)
 
P.90 掲載の参考文献
1) 日本の大規模コホート研究 [http://jeaweb.jp/activities/cohort.html] (2017年9月閲覧)
 
2) Inoue M, et al : Evaluation based on systematic review of epidemiological evidence among Japanese populations : tobacco smoking and total cancer risk. Jpn J Clin Oncol 35 : 404-411, 2005.
PubMed
3) Inoue M, et al : Impact of tobacco smoking on subsequent cancer risk among middle-aged Japanese men and women : data from a large-scale population-based cohort study in Japan-the JPHC study. Prev Med 38 : 516-522, 2004.
PubMed
4) Wakai K, et al : Decrease in risk of lung cancer death in males after smoking cessation by age at quitting : findings from the JACC study. Jpn J Cancer Res 92 : 821-828, 2001.
PubMed
5) Inoue M, et al : Impact of alcohol intake on total rnortality and mortality from major causes in Japan : a pooled analysis of six large-scale cohort studies. J Epidemiol Community Health 66 : 448-456, 2012.
PubMed
6) Inoue M, et al : Daily total physical activity level and total cancer risk in men and women : results from a large-scale population-based cohort study in Japan. Am J Epidemiol 168 : 391-403, 2008.
PubMed
7) Ukawa S, et al : Prospective cohort study on television viewing time and incidence of lung cancer : findings from the Japan Collaborative Cohort Study. Cancer Causes Control 24 : 1547-1553, 2013.
PubMed
8) Sasazuki S, et al : Body mass index and mortality from all causes and major causes in Japanese : results of a pooled analysis of 7 large-scale cohort studies. J Epidemiol 21 : 417-430, 2011.
PubMed
9) 生活習慣病改善によるがん予防法の開発に関する研究. [http://epi.ncc.go.jp/cgi-bin/cms/public/index.cgi/nccepi/can_prev/outcome/index] (2017年9月閲覧)
 
10) Takachi R, et al : Fruit and vegetable intake and the risk of overall cancer in Japanese : A pooled analysis of population-based cohort studies. J Epidemiol 27 : 152-162, 2017.
PubMed
11) Takachi R, et al : Consumption of sodium and salted foods in relation to cancer and cardiovascular disease : the Japan Public Health Center-based Prospective Study. Am J Clin Nutr 91 : 456-464, 2010.
PubMed
12) Ikehara S, et al : Association of sleep duration with mortality from cardiovascular disease and other causes for Japanese men and women : the JACC study. Sleep 32 : 295-301, 2009.
PubMed
13) Sasazuki S, et al : Combined impact of five lifestyle factors and subsequent risk of cancer : the Japan Public Health Center Study. Prev Med 54 : 112-116, 2012.
PubMed
P.95 掲載の参考文献
1) Song M, et al : Asia Cohort Consortium : challenges for collaborative research. J Epidemiol 22 : 287-290, 2012.
 
2) Zheng W, et al : Association between body-mass index and risk of death in more than l million Asians. N Engl J Med 364 : 719-729, 2011.
 
3) Boffetta P, et al : Body mass, tobacco smoking, alcohol drinking and risk of cancer of the small intestine-a pooled analysis of over 500,000 subjects in the Asia Cohort Consortium. Ann Oncol 23 : 1894-1898, 2012.
PubMed
4) Lin Y, et al : Association of body mass index and risk of death from pancreas cancer in Asians : findings from the Asia Cohort Consortium. Eur J Cancer Prev 22 : 244-250, 2013.
PubMed
5) Fowke JH, et al : Associations of body mass index, smoking, and alcohol consumption with prostate cancer mortality in the Asia Cohort Consortium. Am J Epidemiol 182 : 381-389, 2015.
PubMed
6) Chen Y, et al : Association between type 2 diabetes and risk of cancer mortality : apooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia 60 : 1022-1032, 2017.
PubMed
P.100 掲載の参考文献
1) World Cancer Research Fund International, Continuous Update Project (CUP) : [http://www.wcrf.org/int/research-we-fund/continuous-update-project-cup] /American Institute for Cancer Research, Continuous Update Project : [http://www.aicr. org/continuous-update-project/] (2017年9月閲覧)
 
2) Cho E, et al : Alcohol intake and colorectal cancer : a pooled analysis of 8 cohort studies. Ann Intern Med 140 : 603-613, 2004.
PubMed
3) Genkinger JM, et al : Alcohol intake and pancreatic cancer risk : a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev 18 : 765-776, 2009.
 
4) Smith-Warner SA, et al : Alcohol and breast cancer in women : a pooled analysis of cohort studies. JAMA 279 : 535-540, 1998.
PubMed
5) Lee JE, et al : Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst 99 : 801-810, 2007.
 
6) Koushik A, et al : Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst 99 : 1471-1483, 2007.
 
7) Smith-Warner SA, et al : Fruits, vegetables and lung cancer : a pooled analysis of cohort studies. Int J Cancer 107 : 1001-1011, 2003.
PubMed
8) Lee JE, et al : Intakes of fruit, vegetables, and carotenoids and renal cell cancer risk : apooled analysis of 13 prospective studies. Cancer Epidemiol Biomarkers Prev 18 : 1730-1739, 2009.
PubMed
P.104 掲載の参考文献
1) United Nations Scientific Committee on the Effects of Atomic Radiation : Annex B. Exposures of the public and workers from various sources of radiation. UNSCEAR 2008 Report Volume I. Sources and effects of ionizing radiation with annexes, United Nations, 2010.
 
2) ICRP : Managing Patient Dose in Computed Tomography : ICRP Publication 87. Ann ICRP 30 (4), 2000.
 
3) United Nations Scientific Committee on the Effects of Atomic Radiation : UNSCEAR 2006 Report Volume I. Scientific Annex A. Epidemiological studies of radiation and cancer, United Nations, 2008.
 
4) Kamiya K, et al : Long-term effects of radiation exposure on health. Lancet 386 : 469-478, 2015.
PubMed
5) Hsu WL, et al : The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors : 1950-2001. Radiat Res 179 : 361-382, 2013.
PubMed
6) 朝長万左男 : 原爆被爆者の白血病と骨髄異形成症候群 (MDS). 広島県医師会速報第2073 : 40-44, 2010.
 
7) Grant EJ, et al : Solid Cancer Incidence among the Life Span Study of Atomic Bomb Survivors : 1958-2009. Radiat Res 187 : 513-537, 2017.
 
8) United Nations Scientific Committee on the Effects of Atomic Radiation : Annex D. Health effects due to radiation from the Chernobyl accident. UNSCEAR 2008 Report Volume II. Sources and effects of ionizing radiation, United Nations, 2011.
 
9) Ron E, et al : Thyroid cancer after exposure to external radiation : apooled analysis of seven studies. Radiat Res 141 : 259-277, 1995.
PubMed
10) Cardis E, Hatch M : The Chernobyl accident-an epidemiological perspective. Clin Oncol (R Coll Radiol) 23 : 251-260, 2011.
PubMed
11) 大津留晶, ほか : 甲状腺がんと放射線障害. 日本内科学会雑誌 104 : 593-599, 2015.
 
12) Land CE, et al : Radiation-associated lung cancer : a comparison of the histology of lung cancers in uranium miners and survivors of the atomic bombings of Hiroshima and Nagasaki. Radiat Res 134 : 234-243, 1993.
PubMed
13) Sugiyama H, et al : Skin cancer incidence among atomic bomb survivors from 1958 to 1996. Radiat Res 181 : 531-539, 2014.
PubMed
14) Samartzis D, et al : Ionizing radiation exposure and the development of soft-tissue sarcomas in atomic-bomb survivors. J Bone Joint Surg Am 95 : 222-229, 2013.
PubMed
15) Davis FG, et al : Cancer mortality in a radiation-exposed cohort of Massachusetts tuberculosis patients. Cancer Res 49 : 6130-6136, 1989.
 
16) Boice JD, et al : Risk of breast cancer following low-dose radiation exposure. Radiology 131 : 589-597, 1979.
PubMed
P.111 掲載の参考文献
1) Yang SJ, et al : Relationship between genetic polymorphisms of ALDH2 and ADH1B and esophageal cancer risk : a meta-analysis. World J Gastroenterol 16 : 4210-4220, 2010.
 
2) Travis RC, et al : Gene-environment interactions in 7610 women with breast cancer : prospective evidence from the Million Women Study. Lancet 375 : 2143-2151, 2010.
PubMed
3) Milne RL, et al : Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium : a combined case-control study. Breast Cancer Res 12 : R110, 2010.
 
4) Campa D, et al : Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst 103 : 1252-1263, 2011.
PubMed
5) Rudolph A, et al : Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. Int J Cancer 136 : E685-696, 2015.
PubMed
6) Palmer TM, et al : Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. Am J Epidemiol 173 : 1392-1403, 2011.
PubMed
7) Brookhart MA, et al : Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf 19 : 537-554, 2010.
 
8) Thrift AP, et al : Obesity and risk of esophageal adenocarcinoma and Barrett'sesophagus : a Mendelian randomization study. J Natl Cancer Inst 106. pii : dju252, 2014.
 
9) Allin KH, et al : C-reactive protein and the risk of cancer : a mendelian randomization study. J Natl Cancer Inst 102 : 202-206, 2010.
 
10) Gail MH : Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 100 : 1037-1041, 2008.
 
11) Chen J, et al : Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98 : 1215-1226, 2006.
PubMed
12) Wacholder S, et al : Performance of common genetic variants in breast-cancer risk models. N Engl J Med 362 : 986-993, 2010.
PubMed
13) Mavaddat N, et al : Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 107. pii : djvO36, 2015.
 
14) Michailidou K, et al : Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45 : 353-361, 361e1-2, 2013.
 
P.115 掲載の参考文献
1) Kune GA, et al : Colorectal cancer risk, chronic illnesses, operations, and medications : case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48 : 4399-4404, 1988.
PubMed
2) Flossmann E, et al : Effect of aspirin on long-term risk of colorectal cancer : consistent evidence from randomised and observational studies. Lancet 369 : 1603-1613, 2007.
PubMed
3) Chan AT, et al : Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134 : 21-28, 2008.
PubMed
4) Cole BF, et al : Aspirin for the chemoprevention of colorectal adenomas : meta-analysis of the randomized trials. J Natl Cancer Inst 101 : 256-266, 2009.
PubMed
5) Ishikawa H, et al : The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients : a randomised trial. Gut 63 : 1755-1759, 2014.
PubMed
6) Gann PH, et al : Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85 : 1220-1224, 1993.
 
7) Cook NR, et al : Low-dose aspirin in the primary prevention of cancer : the Women's Health Study : a randomized controlled trial. JAMA 294 : 47-55, 2005.
PubMed
8) Rothwell PM, et al : Long-term effect of aspirin on colorectal cancer incidence and mortality : 20-year follow-up of five randomised trials. Lancet 376 : 1741-1750, 2010.
PubMed
9) Burn J, et al : Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359 : 2567-2578, 2008.
 
10) Burn J, et al : Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer : an analysis from the CAPP2 randomised controlled trial. Lancet 378 : 2081-2087, 2011.
PubMed
11) Bibbins-Domingo K, et al : Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer : U. S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164 : 836-845, 2016.
PubMed
12) Pommergaard HC, et al : Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. Gastroenterology 150 : 114-122. e4, 2016.
 
13) Drew DA, et al : Colorectal polyp prevention by daily aspirin use is abrogated among active smokers. Cancer Causes Control 27 : 93-103, 2016.
PubMed
14) Nan H, et al : Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 313 : 1133-1142, 2015.
PubMed
P.120 掲載の参考文献
1) Andriole GL, et al : Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 : 1310-1319, 2009.
 
2) Bettuzzi S, et al : Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia : a preliminary report from a one-year proof-of-principle study. Cancer Res 66 : 1234-1240, 2006.
PubMed
3) Cui K, et al : Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN) : a systematic review and adjusted indirect treatment comparison. Oncotarget 8 : 36674-36684, 2017.
PubMed
4) World Cancer Research Fund and American Institute for Cancer Research : Food, Nutrition, Physical Activity, and the Prevention of Cancer : a Global Perspective, p305-309, American Institute for Cancer Research, Washington DC, 2007.
 
5) World Cancer Research Fund International : Continuous Update Project (Cup). [http://www.wcrf.org/int/research-we-fund/continuous-update-project-cup] (2017年9月閲覧)
 
6) Thompson IM, et al : The influence of finasteride on the development of prostate cancer. N Engl J Med 349 : 215-224, 2003.
PubMed
7) Lucia MS, et al : Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 : 1375-1383, 2007.
 
8) Andriole GL, et al : Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362 : 1192-1202, 2010.
PubMed
9) Akaza H, et al : Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men : the results from the REDUCE study. Jpn J Clin Oncol 41 : 417-423, 2011.
PubMed
10) Kramer BS, et al : Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention : American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 27 : 1502-1516, 2009.
 
11) Lippman SM, et al : Effect of selenium and vitamin E on risk of prostate cancer and other cancers : the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301 : 39-51, 2009.
PubMed
12) Gaziano JM, et al : Vitamins E and C in the prevention of prostate and total cancer in men : the Physicians' Health Study II randomized controlled trial. JAMA 301 : 52-62, 2009.
 
13) Price D, et al : Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia : results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 176 : 965-970 : discussion 970-971, 2006.
 
14) Taneja SS, et al : Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol 31 : 523-529, 2013.
PubMed
15) Yan L, Spitznagel EL : Soy consumption and prostate cancer risk in men : a revisit of a meta-analysis. Am J Clin Nutr 89 : 1155-1163, 2009.
 
16) Fleshner NE, et al : Progression from high-grade prostatic intraepithelial neoplasia to cancer : a randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol 29 : 2386-2390, 2011.
 
17) Kumar NB, et al : Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila) 8 : 879-887, 2015.
PubMed
18) Ross RK, et al : 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339 : 887-889, 1992.
PubMed
19) Milonas D, et al : Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia : results of a phase III randomized open-label 3-year trial. World J Urol 35 : 721-728, 2017.
PubMed
20) Gontero P, et al : A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"? Prostate 75 : 1177-1186, 2015.
PubMed
21) Gann PH, et al : A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia. Nutr Cancer 67 : 1104-1112, 2015.
PubMed
22) Marshall JR, et al : Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia : SWOG S9917. Cancer Prev Res (Phila) 4 : 1761-1769, 2011.
PubMed
23) Zanardi S, et al : Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies. Cancer Prev Res (Phila) 2 : 377-384, 2009.
PubMed
24) Bono AV, et al : Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN : findings in repeat biopsies at 6 months. J Clin Pathol 60 : 443-446, 2007.
PubMed
25) Mohanty NK, et al : Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urol Oncol 23 : 383-385, 2005.
PubMed

III がん転移学の基礎研究

P.129 掲載の参考文献
1) Murphy DA, Courtneidge SA : The 'ins' and 'outs' of podosomes and invadopodia : characteristics, formation and function. Nat Rev Mol Cell Biol 12 : 413-426, 2011.
PubMed
2) Fischer KR, et al : Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 : 472-476, 2015.
 
3) Ye X, et al : Upholding a role for EMT in breast cancer metastasis. Nature 547 : E1-E3, 2017.
PubMed
4) Watanebe S : The metastasizability of tumor cells. Cancer 7 : 215-223, 1954.
 
5) Labelle M, Hynes RO : The initial hours of metastasis : the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2 : 1091-1099, 2012.
PubMed
6) Labelle M, et al : Direct signaling between platelets and cancer cells induces an epithelialmesenchymal-like transition and promotes metastasis. Cancer Cell 20 : 576-590, 2011.
 
7) Cools-Lartigue J, et al : Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest, 2013. [Epub ahead of print]
 
8) Labelle M, et a1 : Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA 111 : E3053-3061, 2014.
 
9) Strilic B, et al : Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature 536 : 215-218, 2016.
PubMed
10) Mani SA, et a1 : The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 : 704-715, 2008.
 
11) Oskarsson T, et al : Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 17 : 867-874, 2011.
PubMed
12) Shiozawa Y, et al : Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121 : 1298-1312, 2011.
PubMed
13) Kaplan RN, et al : VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 438 : 820-827, 2005.
 
14) Hoshino A, et al : Tumour exosome integrins determine organotropic metastasis. Nature 527 : 329-335, 2015.
PubMed
15) Yumimoto K, et al : F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. J Clin Invest 125 : 621-635, 2015.
 
16) Brabletz T : To differentiate or not-routes towards metastasis. Nat Rev Cancer 12 : 425-436, 2012.
 
17) Takeishi S, et al : Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 23 : 347-361, 2013.
PubMed
P.135 掲載の参考文献
1) Ye X, Weinberg RA : Epithelial-Mesenchymal Plasticity : A Central Regulator of Cancer Progression. Trends Cell Biol 25 : 675-686, 2015.
PubMed
2) Steeg PS : Targeting metastasis. Nat Rev Cancer 16 : 201-218, 2016.
PubMed
3) Bekes EM, et al : Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol 179 : 1455-1470, 2011.
PubMed
4) Francia G, et al : Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 11 : 135-141, 2011.
PubMed
5) Pascual G, et al : Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541 : 41-45, 2017.
PubMed
6) Paez-Ribes M, et al : Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis : A Cautionary Note. PLoS ONE 11 : e0158034, 2016.
PubMed
7) Muramatsu T, et al : The hypusine cascade promotes cancer progression and metastasis through the regulation of RhoA in squamous cell carcinoma. Oncogene 35 : 5304-5316, 2016.
PubMed
8) Shih IeM, et al : Amplification of the ch19p132 NACC1 locus in ovarian high-grade serous carcinoma. Mod Pathol 24 : 638-645, 2011.
PubMed
9) Kaiser A : Translational control of elF5A in various diseases. Amino Acids 42 : 679-684, 2012.
 
10) Scuoppo C, et al : A tumour suppressor network relying on the polyamine-hypusine axis. Nature 487 : 244-248, 2012.
PubMed
11) Fujimura K, et al : A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer. Cancer Res 74 : 6671-6681, 2014.
PubMed
12) Pallmann N, et al : Biological Relevance and Therapeutic Potential of the Hypusine Modification System. J Biol Chem 290 : 18343-18360, 2015.
PubMed
13) Fujimura K, et al : Eukaryotic Translation lnitiation Factor 5A (EIF5A) Regulates Pancreatic Cancer Metastasis by Modulating RhoA and Rho-associated Kinase (ROCK) Protein Expression Levels. J Biol Chem 290 : 29907-29919, 2015.
 
14) Gutierrez E, et al : eIF5A promotes translation of polyproline motifs. Mol Cell 51 : 35-45, 2013.
PubMed
15) Aksu M, et al : Structure of the exportin Xpo4 in complex with RanGTP and the hypusine-containing translation factor elFsA. Nat Commun 7 : 11952, 2016.
PubMed
16) Xu A, Chen KY : Hypusine is required for a sequence-specific interaction of eukaryotic initiation factor 5A with postsystematic evolution of ligands by exponential enrichment RNA. J Biol Chem 276 : 2555-2561, 2001.
PubMed
17) Maier B, et al : The unique hypusine modification of eIFsA promotes islet beta cell inflammation and dysfunction in mice. J Clin Invest 120 : 2156-2170, 2010.
 
18) Minden MD, et al : Oral ciclopirox olamine displays biological activity in a phase 1 study in patients with advanced hematologic malignancies. Am J Hematol 89 : 363-368, 2014.
 
19) Memin E, et al : Blocking eIF5A modification in cervical cancer cells alters the expression of cancerrelated genes and suppresses cell proliferation. Cancer Res 74 : 552-562, 2014.
 
20) Balabanov S. et al : Hypusination of eukaryotic initiation factor 5A (eIF5A) : a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 109 : 1701-1711, 2007.
PubMed
21) Bhat M, et al : Targeting the translation machinery in cancer. Nat Rev Drug Discov 14 : 261-278, 2015.
PubMed
22) Duffy AG, et al : Modulation of tumor eIF4E by antisense inhibition : A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against elF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. Int J Cancer 139 : 1648-1657, 2016.
 
P.142 掲載の参考文献
1) Magee JA, et al : Cancer stem cells : impact, heterogeneity, and uncertainty. Cancer Cell 21 : 283-296, 2012.
PubMed
2) Eun K, et al : Cancer stem cell heterogeneity : origin and new perspectives on CSC targeting. BMB Rep 50 : 117-125, 2017.
PubMed
3) Wainwright EN, et al : Epigenetics and cancer stem cells : Unleashing, hijacking, and restricting cellular plasticity. Trends Cancer 3 : 372-386, 2017.
PubMed
4) Toh TB, et al : Epigenetics in cancer stem cells. Mol Cancer 16 : 29, 2017.
PubMed
5) Natsume A, et al : Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res 73 : 4559-4570, 2013.
PubMed
6) Katsushima K, et al : Contribution of microRNA-1275 to Claudinll protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells. J Biol Chem 287 : 27396-27406, 2012.
 
7) Mineo M, et al : The Long Non-coding RNA HIFIA-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. Cell Rep 15 : 2500-2509, 2016.
 
8) Jiang Y, et al : The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor l. Tumour Biol 37 : 3957-3967, 2016.
 
9) Deng J, et al : Long non-coding RNA HOTAIR regulates the proliferation, self-renewal capacity, tumor formation and migration of the cancer stem-like cell (CSC) subpopulation enriched from breast cancer cells. PLoS ONE 12 : e0170860, 2017.
PubMed
10) Zhu P, et al : Inc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC selfrenewal. Nat Struct Mol Biol 23 : 631-639, 2016.
 
11) Zhou M, et al : LncRNA-Hh Strengthen Cancer Stem Cells Generation in Twist-Positive Breast Cancer via Activation of Hedgehog Signaling Pathway. Stem Cells 34 : 55-66, 2016.
PubMed
12) Wang Y, et al : The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell 16 : 413-425, 2015.
 
13) Xia F, et al : Interaction of lincRNA ROR and p53/miR-145 correlates with lung cancer stem cell signatures. J Cell Biochem, 2017. [Epub ahead of print]
 
14) Jiao F, et al : Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci 16 : 6677-6693, 2015.
PubMed
15) Katsushima K, et al : Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun 7 : 13616, 2016.
PubMed
16) ENCODE Project Consortium : An integrated encyclopedia of DNA elements in the human genome. Nature 489 : 57-74, 2012.
PubMed
17) Iyer MK, et al : The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 47 : 199-208, 2015.
PubMed
18) Wen PY, Kesari S : Malignant gliomas in adults. N Engl J Med 359 : 492-507, 2008.
PubMed
P.148 掲載の参考文献
1) Weinberg RA : The Biology of Cancer. 2nd ed, Garland Science, New York, 2014.
 
2) Koizumi K, et al : Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 98 : 1652-1658, 2007.
PubMed
3) Ishiwata T : Cancer stem cells and epithelial-mesenchymal transition : Novel therapeutic targets for cancer. Pathol Int 66 : 601-608, 2016.
PubMed
4) Takeichi M : The cadherin superfamily in neuronal connections and interactions. Nat Rev Neurosci 8 : 11-20, 2007.
PubMed
5) Sakisaka T, Takai Y : Biology and pathology of nectins and nectin-like molecules. Curr Opin Cell Biol 16 : 513-521, 2004.
PubMed
6) Hajra KM, Fearon ER : Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34 : 255-268, 2002.
PubMed
7) Ino Y, et al : Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Proc Natl Acad Sci USA 99 : 365-370, 2002.
PubMed
8) Hirohashi S, Kanai Y : CeU adhesion system and human cancer morphogenesis. Cancer Sci 94 : 575-581, 2003.
 
9) Kuramochi M, et al : TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 27 : 427-430, 2001.
PubMed
10) Murakami Y : Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci 96 : 543-552, 2005.
PubMed
11) Sakurai-Yageta M, et al : Dynamic regulation of a cell adhesion protein complex including CADM1 by combinatorial analysis of FRAP with exponential curve-fitting. PLoS ONE 10 : e0116637, 2015.
PubMed
12) Sakurai-Yageta M, et al : Tumor suppressor CADM1 is involved in epithelial cell structure. Biochem Biophys Res Commun 390 : 977-982, 2009.
PubMed
13) Goto A, et al : Loss of TSLC1 expression in lung adenocarcinoma : relationships with histological subtypes, sex and prognostic significance. Cancer Sci 96 : 480-486, 2005.
PubMed
14) Masuda M, et al : Tumor suppressor in lung cancer (TSLC) 1 suppresses epithelial cell scattering and tubulogenesis. J Biol Chem 280 : 42164-42171, 2005.
PubMed
15) Arase N, et al : Heterotypic interaction of CRTAM with Necl2 induces cell adhesion on activated NK cells and CD8+ T cells. Int Immunol 17 : 1227-1237, 2005.
PubMed
P.157 掲載の参考文献
1) St Croix B, et al : Genes expressed in human tumor endothelium. Science 289 : 1197-1202, 2000.
PubMed
2) Folkman J : Tumor angiogenesis : therapeutic implications. N Engl J Med 285 : 1182-1186, 1971.
PubMed
3) Stacker SA, et al : Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 14 : 159-172, 2014.
PubMed
4) Ishii G, et al：Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev 99 : 186-196, 2016.
PubMed
5) Katayama R, et al : Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4 : 120ra17, 2012.
PubMed
6) Takemoto A, et al : Platelet-activating factor podoplanin : from discovery to drug development. Cancer Metastasis Rev 36 : 225-234, 2017.
PubMed
7) Colegio OR, et al : Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 : 559-563, 2014.
 
8) Kunita A, et al : The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 170 : 1337-1347, 2007.
PubMed
9) Takagi S, et al : Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS ONE 8 : e73609, 2013.
PubMed
10) Best MG, et al : RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell 28 : 666-676, 2015.
PubMed
11) Fujita Y, et al : Extracellular vesicle transfer of cancer pathogenic components． Cancer Sci 107 : 385-390, 2016.
PubMed
12) Yachida S, et al : Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 : 1114-1117, 2010.
PubMed
13) Clifford SC : Cancer genetics：Evolution after tumour spread. Nature 482 : 481-482, 2012.
PubMed
14) Katayama R, et al : Therapeutic targeting of anaplastic lymphoma kinase in lung cancer : a paradigm for precision cancer medicine. Clin Cancer Res 21 : 2227-2235, 2015.
PubMed
15) Mertens JC, et al : Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res 73 : 897-907, 2013.
PubMed
P.162 掲載の参考文献
1) Leemans CR et al : The molecular biology of head and neck cancer. Nat Rev Cancer 11 : 9-22, 2011.
PubMed
2) de Juan J, et al : Inclusion of extracapsular spread in the pTNM classification system : a proposal for patients with head and neck carcinoma. JAMA Otolaryngol Head Neck Surg 139 : 483-488, 2013.
PubMed
3) Valastyan S, Weinberg RA : Tumor metastasis : molecular insights and evolving paradigms. Cell 147 : 275-292, 2011.
PubMed
4) Sakamoto K, et al : Overexpression of SIPI and downregulation of E-cadherin predict delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma after partial glossectomy. Ann Surg Oncol 19 : 612-619, 2012.
 
5) Peitzsch C, et al : Cancer stem cells : The root of tumor recurrence and metastases. Semin Cancer Biol 44 : 10-24, 2017.
PubMed
6) Habu N, et al : Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma. BMC Cancer 15 : 730, 2015.
 
7) Cancer Genome Atlas Network : Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517 : 576-582, 2015.
PubMed
8) Mroz EA, et al : Intra-tumor genetic heterogeneity and mortality in head and neck cancer : analysis of data from the Cancer Genome Atlas. PLoS Med 12 : e1001786, 2015.
PubMed
9) Ledgerwood LG, et al : The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget 7 : 27185-27198, 2016.
PubMed
10) Zhang XC, et al : Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing. Neoplasia 15 : 1371-1378, 2013.
PubMed
11) Hedberg ML, et al : Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest 126 : 169-180, 2016.
PubMed
P.168 掲載の参考文献
1) EBMの手法による肺癌診療ガイドライン 2016年版 悪性胸膜中皮腫・胸腺腫瘍含む, 第4版, 金原出版, 2016.
 
2) Weinstein IB, Joe A : Oncogene addiction. Cancer Res 68 : 3077-3080 ; discussion 3080, 2008.
 
3) Redig AJ, et al : Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. Clin Cancer Res 22 : 3148-3156, 2016.
PubMed
4) Campbell JD, et al : Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 48 : 607-616, 2016.
PubMed
5) de Bruin EC, et al : Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346 : 251-256, 2014.
PubMed
6) Zhang J, et al : Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346 : 256-259, 2014.
PubMed
7) Yatabe Y, et al : Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29 : 2972-2977, 2011.
PubMed
8) Skoulidis F, et al : Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5 : 860-877, 2015.
PubMed
9) Paik PK, et al : Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. Cancer Discov 5 : 610-621, 2015.
PubMed
10) Westcott PM, et al : The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517 : 489-492, 2015.
PubMed
11) Suda K, et al : Biological and clinical significance of KRAS mutations in lung cancer : an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29 : 49-60, 2010.
PubMed
12) Konduri K, et al : EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov 6 : 601-611, 2016.
PubMed
13) Lim SH, et al : Efficacy and safety of dovitinib in pretreated patients with advanced squamous nonsmall cell lung cancer with FGFR1 amplification : A single-arm, phase 2 study. Cancer 122 : 3024-3031, 2016.
PubMed
14) Cancer Genome Atlas Research Network : Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 : 519-525, 2012.
 
15) Ferone G, et al : SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin. Cancer Cell 30 : 519-532, 2016.
PubMed
P.173 掲載の参考文献
1) Seery Jp : Stem cells of the oesophageal epithelium. J Cell Sci 115 : 1783-1789, 2002.
PubMed
2) Isohata N, et al : Hedgehog and epithelial-mesenchymal transition signaling in normal and malignant epithelial cells of the esophagus. Int J Cancer 125 : 1212-1221, 2009.
PubMed
3) Van Dop WA, et al : Hedgehog signalling stimulates precursor cell accumulation and impairs epithelial maturation in the murine oesophagus. Gut 62 : 348-357, 2013.
PubMed
4) Sims-Mourtada J, et al : Hedgehog : an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 12 : 6565-6572, 2006.
 
5) Yoshikawa R, et al : Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. Br J Cancer 98 : 1670-1674, 2008.
PubMed
6) Ashida A, et al : Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy : clinical implications. Int J Oncol 28 : 1345-1352, 2006.
PubMed
7) Luthra R, et al : Gene expression profiling of localized esophageal carcinomas : association with pathologic response to preoperative chemoradiation. J Clin Oncol 24 : 259-267, 2006.
PubMed
8) Nishimura T, et al : SIX1 maintains tumor basal cells via transforming growth factor-β pathway and associates with poor prognosis in esophageal cancer. Cancer Sci 108 : 216-225, 2017.
 
9) Tanaka Y, et al : Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy. PLoS ONE 10 : e0143804, 2015.
PubMed
10) Yamada A, et al : Expression of cytokeratin 7 predicts survival in stage I/IIA/IIB squamous cell carcinoma of the esophagus. Oncol Rep 20 : 1021-1027, 2008.
 
11) Sano M, et al : Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamous cell carcinomas with extensive lymph node metastasis. Int J Oncol 36 : 321-330, 2010.
PubMed
12) Song Y, et al : Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509 : 91-95, 2014.
PubMed
13) Sawada G, et al : Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. Gastroenteroiogy 150 : 1171-1182, 2016.
 
P.179 掲載の参考文献
1) Lauren P : The Two Histological Main Types of Gastric Carcinoma : Diffuse and So-called Intestinaltype Carcinoma. An Attempt at a Histo-cinical Classification. Acta Pathol Microbiol Scand 64 : 31-49, 1965.
 
2) WHO CIassification of Tumours of the Digestive System, 4th edn International Agency for Research on Cancer, Lyon, 2010.
 
3) Tan P, et al : Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. Gastroenterology 149 : 1153-1162. e3, 2015.
 
4) Kakiuchi M, et al : Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 46 : 583-587, 2014.
PubMed
5) Cancer Genome Atlas Research Network : Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 : 202-209, 2014.
 
6) Chia NY, et al : Molecular classification of gastric cancer. Ann Oncol 27 : 763-769, 2016.
PubMed
7) Nakamura J, et al : Methylation-mediated gene silencing as biomarkers of gastric cancer : a review. World J Gastroenterol 20 : 11991-12006, 2014.
PubMed
8) Asada K, et al : Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut 64 : 388-396, 2015.
PubMed
9) Nakajima T, et al : Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 15 : 2317-2321, 2006.
PubMed
10) Kurashige J, et al : Integrated Molecular Profiling of Human Gastric Cancer Identifies DDR2 as a Potential Regulator of Peritoneal Dissemination. Sci Rep 6 : 22371, 2016.
PubMed
11) Zhang L, et al : Genome-wide analysis of histone H3 lysine 27 trimethylation by ChlP-chip in gastric cancer patients. J Gastroenterol 44 : 305-312, 2009.
 
12) Nambara S, et al : Overexpression of CXCR7 Is a Novel Prognostic Indicator in Gastric Cancer. Dig Surg 34 : 312318, 2017.
 
13) Uchi R, et al : PICT1 regulates TP53 via RPL11 and is involved in gastric cancer progression. Br J Cancer 109 : 2199-2206, 2013.
PubMed
14) Yokobori T, et al : p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 69 : 3788-3794, 2009.
PubMed
15) Tan IB, et al : Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141 : 476-485, 485. e1-11, 2011.
 
16) Nishida N, et al : MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 17 : 2725-2733, 2011.
PubMed
17) Akiyoshi S, et al : Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br J Cancer 107 : 1345-1353, 2012.
PubMed
18) Kogo R, et al : Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res 17 : 4277-4284, 2011.
PubMed
19) Kurashige J, et al : Epigenetic modulation and repression of miR-200b by cancer-associated fibroblasts contribute to cancer invasion and peritoneal dissemination in gastric cancer. Carcinogenesis 36 : 133-141, 2015.
PubMed
20) Iwaya T, et al : Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer. Clin Cancer Res 19 : 6438-6449, 2013.
 
21) Wu Y, et al : Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut 62 : 1100-1111, 2013.
PubMed
22) El-Omar EM, et al : Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 : 398-402, 2000.
PubMed
23) Tsujiura M, et al : Liquid biopsy of gastric cancer patients : circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 20 : 3265-3286, 2014.
PubMed
24) Beeharry MK, et al : New blood markers detection technology : A leap in the diagnosis of gastric cancer. World J Gastroenterol 22 : 1202-1212, 2016.
 
25) Ueda M, et al : Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence. Oncotarget 7 : 62280-62291, 2016.
PubMed
26) Taniguchi H, et al : Cancer stem cells in human gastrointestinal cancer. Cancer Sci 107 : 1556-1562, 2016.
PubMed
27) Kelly RJ : Immunotherapy for Esophageal and Gastric Cancer. Am Soc Clin Oncol Educ Book 37 : 292-300, 2017.
PubMed
P.184 掲載の参考文献
1) Vogelstein B, et al : Genetic alterations during colorectal-tumor development N Engl J Med 319 : 525-532, 1988.
PubMed
2) Leggett B, Whitehall V : Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 138 : 2088-2100, 2010.
PubMed
3) Fearon ER : Molecular genetics of colorectal cancer. Annu Rev Pathol 6 : 479-507, 2011.
PubMed
4) Segditsas S, Tomlinson I : Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25 : 7531-7537, 2006.
PubMed
5) Weisenberger DJ, et al : CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cance蛤Nat Genet 38 : 787-793, 2006.
 
6) Duval A, Hamelin R : Mutations at coding repeat sequences in mismatch repair-deficient human cancers : toward a new concept of target genes for instability. Cancer Res 62 : 2447-2454, 2002.
 
7) Smith G, et al : Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 99 : 9433-9438, 2002.
PubMed
8) Cancer Genome Atlas Network : Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 : 330-337, 2012.
PubMed
9) Sadanandam A, et al : A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19 : 619-625, 2013.
 
10) Le DT, et al : PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372 : 2509-2520, 2015.
PubMed
P.191 掲載の参考文献
1) Shibata T, Aburatani H : Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol 11 : 340-349, 2014.
PubMed
2) Zucman-Rossi J, et al : Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 149 : 1226-1239. e4, 2015.
 
3) 加藤直也 : 肝細胞癌のゲノム解析. 日本消化器病学会雑誌 113 : 767-774, 2016.
Medical*Online
4) 山下太郎, ほか : 肝細胞癌基礎研究の課題と展望. 日本臨牀 73 (増刊号 : 最新肝癌学) : 27-32, 2015.
 
5) Totoki Y, et al : High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 43 : 464-469, 2011.
PubMed
6) Fujimoto A, et al : Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44 : 760-764, 2012.
PubMed
7) Kan Z, et al : Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 23 : 1422-1433, 2013.
PubMed
8) Totoki Y, et al : Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46 : 1267-1273, 2014.
PubMed
9) Schulze K, et al : Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47 : 505-511, 2015.
PubMed
10) Fujimoto A, et al : Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet 48 : 500-509, 2016.
PubMed
11) Cancer Genome Atlas Research Network, et al : Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169 : 1327-1341. e23, 2017.
 
12) Saito T, et al : p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun 7 : 12030, 2016.
PubMed
13) Alexandrov LB, et al : Signatures of mutational processes in human cancer. Nature 500 : 415-421, 2013.
PubMed
14) Huang MN et al : Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. Genome Res 27 : 1475-1486, 2017.
PubMed
15) Nault JC, et al : Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 47 : 1187-1193, 2015.
PubMed
16) Hoshida Y, et al : Molecular classification and novel targets in hepatocellular carcinoma : recent advancements. Semin Liver Dis 30 : 35-51, 2010.
PubMed
17) Llovet JM, et al : Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12 : 408-424, 2015.
PubMed
18) Zehir A, et al : Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23 : 703-713, 2017.
PubMed
P.195 掲載の参考文献
1) Nakamura H, et al : Genomic spectra of biliary tract cancer. Nat Genet 47 : 1003-1010, 2015.
PubMed
2) Chen CR, et al : E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 110 : 19-32, 2002.
 
3) Shi J, et al : Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev 27 : 2648-2662, 2013.
PubMed
4) Kipp BR, et al : Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 43 : 1552-1558, 2012.
PubMed
5) Wang P, et al : Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32 : 3091-3100, 2013.
PubMed
6) Rohle D, et al : An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340 : 626-630, 2013.
PubMed
7) Wang F, et al : Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340 : 622-626, 2013.
PubMed
8) Farmer H, et al : Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 : 917-921, 2005.
PubMed
9) Arai Y, et a1 : Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59 : 1427-1434, 2014.
 
10) Borad MJ, et al : Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 10 : e1004135, 2014.
PubMed
11) Javle MM, et al : A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. J Clin Oncol 34 (Suppl 4S) : abstr 335, 2016.
 
12) Le DT, et al : PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372 : 2509-2520, 2015.
PubMed
13) Chaisaingmongkol J, et al : Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 32 : 57-70. e3, 2017.
 
P.201 掲載の参考文献
1) Siegel RL, et al : Cancer Statistics, 2017. CA Cancer J Clin 67 : 7-30, 2017.
 
2) Hezel AF, et al : Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20 : 1218-1249, 2006.
PubMed
3) Hingorani SR, et al : Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 : 469-483, 2005.
PubMed
4) Rhim AD, et al : EMT and dissemination precede pancreatic tumor formation. Cell 148 : 349-361, 2012.
PubMed
5) Valastyan S, Weinberg RA : Tumor metastasis : molecular insights and evolving paradigms. Cell 147 : 275-292, 2011.
PubMed
6) Brabletz T : To differentiate or not-routes towards metastasis. Nat Rev Cancer 12 : 425-436, 2012.
 
7) van Denderen BJ, Thompson EW : Cancer : The to and fro of tumour spread. Nature 493 : 487-488, 2013.
PubMed
8) Nieto MA : The ins and outs of the epithelial to mesenchymal transition in health and disease, Annu Rev Cell Dev Biol 27 : 347-376, 2011.
PubMed
9) Reichert M, et al : Isolation, culture and genetic manipulation of mouse pancreatic ductal cells. Nat Protoc 8 : 1354-1365, 2013.
PubMed
10) Reichert M, et al : The Prrxl homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. Genes Dev 27 : 288-300, 2013.
 
11) Takano S, et al : Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Genes Dev 30 : 233-247, 2016.
PubMed
12) Olive KP, et al : Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 : 1457-1461, 2009.
 
13) Heeg S, et al : ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. Gastroenterology 151 : 540-553. e14, 2016.
 
14) Rhim AD, et al : Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25 : 735-747, 2014.
PubMed
15) Aiello NM, et al : Metastatic progression is associated with dynamic changes in the local microenvironment. Nat Commun 7 : 12819, 2016.
PubMed
P.206 掲載の参考文献
1) Oya M : Renal cell carcinoma : Molecular features and treatment updates, Springer Japan, 2017. DOI : 10.1007/978-4-431-55531-5 (Online).
 
2) Linehan WM, et al : Identification of the genes for kidney cancer : opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13 : 671s-679s, 2007.
PubMed
3) Schmidt L, et al : Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 16 : 68-73, 1997.
PubMed
4) Tomlinson IP, et al : Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30 : 406-410, 2002.
PubMed
5) Nickerson ML, et al : Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dub6 syndrome. Cancer Cell 2 : 157-164, 2002.
 
6) Argani P, et al : PRCC-TFE3 renal carcinomas : morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t (X ; 1) (p11.2 ; q21). Am J Surg Pathol 26 : 1553-1566, 2002.
 
7) Gerlinger M, et al : Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46 : 225-233, 2014.
PubMed
8) Gerlinger M, et al : Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 : 883-892, 2012.
PubMed
9) Varela I, et al : Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469 : 539-542, 2011.
PubMed
10) Hsieh JJ, et al : Renal cell carcinoma. Nat Rev Dis Primers 3 : 17009, 2017.
PubMed
11) Haase VH : Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 291 : F271-281, 2006.
PubMed
12) Horiguchi A, et al : Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 169 : 710-713, 2003.
PubMed
13) Nakaigawa N, et al : Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res 66 : 3699-3705, 2006.
 
14) Choueiri TK, et al : Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR) : final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17 : 917-927, 2016.
PubMed
15) Moch H, et al : The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A : Renal, Penile, and Testicular Tumours. Eur Urol 70 : 93-105, 2016.
 
16) Dunnill MS, et al : Acquired cystic disease of the kidneys : a hazard of long-term intermittent maintenance haemodialysis. J Clin Pathol 30 : 868-877, 1977.
PubMed
17) Foshat M, Eyzaguirre E : Acquired Cystic Disease-Associated Renal Cell Carcinoma : Review of Pathogenesis, Morphology, Ancillary Tests, and Clinical Features. Arch Pathol Lab Med 141 : 600-606, 2017.
PubMed
18) Mikami S, et al : Recent advances in renal cell carcinoma from a pathological point of view. Pathol Int 66 : 481-490, 2016.
PubMed
P.211 掲載の参考文献
1) Dudek AM, et al : Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms? Int J Mol Sci 14 : 12346-12366, 2013.
PubMed
2) Chang DW, et al : Germline prognostic markers for urinary bladder cancer : obstacles and opportunities. Urol Oncol 30 : 524-532, 2012.
PubMed
3) Balbas-Martinez C, et al : Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 45 : 1464-1469, 2013.
 
4) Guo G, et al : Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 45 : 1459-1463, 2013.
PubMed
5) Gui Y, et al : Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43 : 875-878, 2011.
PubMed
6) Cancer Genome Atlas Research Network : Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 : 315-322, 2014.
 
7) Nordentoft I, et al : Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep 7 : 1649-1663, 2014.
PubMed
8) Knowles MA, Hurst CD : Molecular biology of bladder cancer : new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15 : 25-41, 2015.
PubMed
9) Cordon-Cardo C : Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol 42 : 154-165, 2008.
 
10) Knowles MA : Molecular pathogenesis of bladder cancer. Int J Clin Oncol 13 : 287-297, 2008.
PubMed
11) Rampias T, et al : A new tumor suppressor role for the Notch pathway in bladder cancer. Nat Med 20 : 1199-1205, 2014.
PubMed
12) Tsuruta H, et al : Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 66 : 8389-8396, 2006.
PubMed
P.219 掲載の参考文献
1) Robinson D, et al : Integrative clinical genomics of advanced prostate cancer. Cell 161 : 1215-1228, 2015.
PubMed
2) Shafi AA, et al : Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther 140 : 223-238, 2013.
PubMed
3) Shaffer DR, et al : Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13 : 2023-2029, 2007.
PubMed
4) Chen Y, et al : Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8 : 440-448, 2008.
PubMed
5) Azad AA, et al : Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA : Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res 21 : 2315-2324, 2015.
PubMed
6) Yu Z, et al : Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 20 : 1590-1600, 2014.
PubMed
7) Beltran H, et al : Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63 : 920-926, 2013.
PubMed
8) Suzuki H, et al : Codon 877 mutation in the androgen receptor gene in advanced prostate cancer : relation to antiandrogen withdrawal syndrome. Prostate 29 : 153-158, 1996.
PubMed
9) Gottlieb B, et al : The androgen receptor gene mutations database : 2012 update. Hum Mutat 33 : 887-894, 2012.
PubMed
10) Gaddipati Jp, et a1 : Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54 : 2861-2864, 1994.
 
11) Veldscholte J, et al : A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173 : 534-540, 1990.
PubMed
12) Matias PM, et al : Structural basis for the giucocorticoid response in a mutant human androgen receptor (AR (ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45 : 1439-1446, 2002.
 
13) Karantanos T, et al : Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 67 : 470-479, 2015.
PubMed
14) Korpal M, et al : An F876 L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 3 : 1030-1043, 2013.
 
15) Hu R, et al : DiStinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72 : 3457-3462, 2012.
PubMed
16) Antonarakis ES, et al : AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 : 1028-1038, 2014.
PubMed
17) Efstathiou E, et al : Molecular characterization of enzalutamide-treated bone metastatic castrationresistant prostate cancer. Eur Urol 67 : 53-60, 2015.
 
18) Liu LL, et al : Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 33 : 3140-3150, 2014.
PubMed
19) Nyquist MD, et al : TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci USA 110 : 17492-17497, 2013.
PubMed
20) Myung JK, et al : An androgen receptor N-terminal domain antagonist for treating Prostate cancer. J Clin Invest 123 : 2948-2960, 2013.
PubMed
21) Montgomery B, et al : Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies : Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clin Cancer Res 22 : 1356-1363, 2016.
PubMed
22) Antonarakis ES, et al : Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol 1 : 582-591, 2015.
 
23) Henzler C, et al : Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun 7 : 13668, 2016.
PubMed
24) Guo Z, Qiu Y : A new trick of an old molecule : androgen receptor splice variants taking the stage?! Int J Biol sci 7 : 815-822, 2011.
 
P.224 掲載の参考文献
1) Ruf CG, et al : Changes in epidemiologic features of testicular germ cell cancer : age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol 32 : 33, e1-6, 2014.
PubMed
2) Kharazmi E, et al : Cancer Risk in Relatives of Testicular Cancer Patients by Histology Type and Age at Diagnosis : A Joint Study from Five Nordic Countries. Eur Urol 68 : 283-289, 2015.
PubMed
3) Rapley EA, et al : A genome-wide association study of testicular germ cell tumor. Nat Genet 41 : 807-810, 2009.
PubMed
4) Kanetsky PA, et al : Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 41 : 811-815, 2009.
PubMed
5) Litchfield K, et al : Identification of four new susceptibility loci for testicular germ cell tumour. Nat Commun 6 : 8690, 2015.
PubMed
6) Turnbull C, et al : Variants near DMRT1, TERT and ATF71P are associated with testicular germ cell cancer. Nat Genet 42 : 604-607, 2010.
PubMed
7) Ruark E, et al : Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nat Genet 45 : 686-689, 2013.
PubMed
8) Chung CC, et al : Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet 45 : 680-685, 2013.
PubMed
9) Fossa SD, et al : Risk of contralateral testicular cancer : a population-based study of 29,515 U. S. men. J Natl Cancer Inst 97 : 1056-1066, 2005.
 
10) Litchfield K, et al : Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nat Commun 6 : 5973, 2015.
PubMed
11) Cutcutache I, et al : Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas. Eur Urol 68 : 77-83, 2015.
PubMed
12) Honecker F, et al : Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 27 : 2129-2136, 2009.
PubMed
13) Feldman DR, et al : Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clin Cancer Res 20 : 3712-3720, 2014.
 
14) Einhorn LH, et al : Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 29 : 12-13, 2006.
PubMed
15) Litchfield K, et al : Polygenic susceptibility to testicular cancer : implications for personalised health care. Br J Cancer 113 : 1512-1518, 2015.
PubMed
P.230 掲載の参考文献
1) Matsumoto K, et al : Predicting the progression of cervical precursor lesions by human papillomavirus genotyping : a prospective cohort study. Int J Cancer 128 : 2898-2910, 2011.
PubMed
2) Longworth MS, Laimins LA : Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68 : 362-372, 2004.
PubMed
3) Clifford G, et al : Chapter 3 : HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 (Suppl 3) : S3/26-34, 2006.
 
4) 温川恭至, 清野透 : ヒトパピローマウイルスによる発がんの分子機構. ウイルス 58 : 141-154, 2008.
 
5) Akagi K, et al : Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 24 : 185-199, 2014.
PubMed
6) Pett M, Coleman N : Integration of high-risk human papillomavirus : akey event in cervical carcinogenesis? J Pathol 212 : 356-367, 2007.
 
7) Hu Z, et al : Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet 47 : 158-163, 2015.
 
8) Johannsen E, Lambert PF : Epigenetics of human papillomaviruses. Virology 445 : 205-212, 2013.
PubMed
9) Gonzalez-Quintana V, et al : MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review). Oncol Rep 35 : 3-12, 2016.
PubMed
10) Cancer Genome Atlas Research Network, et al : Integrated genomic and molecular characterization of cervical cancer. Nature 543 : 378-384, 2017.
 
11) Grabowska AK, Riemer AB : The invisible enemy-how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J 6 : 249-256, 2012.
PubMed
12) Guess JC, McCance DJ : Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J Virol 79 : 14852-14862, 2005.
PubMed
13) Berti FCB, et al : The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma. Cytokine Growth Factor Rev 34 : 1-13, 2017.
PubMed
14) Lepique AP, et al : HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 15 : 4391-4400, 2009.
PubMed
15) Bulk S, et al : The contribution of HPV18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency. Br J Cancer 96 : 1234-1236, 2007.
PubMed
P.235 掲載の参考文献
1) 国立がん研究センターがん情報サービスがん統計 年次推移. [http://ganjoho.jp/reg_stat/statistics/stat/annual.html] (2017年9月閲覧)
 
2) Bokhman JV : Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15 : 10-17, 1983.
PubMed
3) Deligdisch L, Cohen CJ : Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 56 : 1452-1455, 1985.
PubMed
4) Sugiyama Y, et al : A large-scale gene expression comparison of microdissected, small-sized endometrial cancers with or without hyperplasia matched to same-patient normal tissue. Clin Cancer Res 9 : 5589-5600, 2003.
PubMed
5) Hasumi K, et al : Small endometrial carcinoma 10 mm or less in diameter : clinicopathologic and histogenetic study of 131 cases for early detection and treatment. Cancer Med 2 : 872-880, 2013.
 
6) Murali R, et al : Classification of endometrial carcinoma : more than two types. Lancet Oncol 15 : e268-278, 2014.
PubMed
7) Clarke BA, Gilks CB : Endometrial carcinoma : controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol 63 : 410-415, 2010.
PubMed
8) Gilks CB, et al : Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 37 : 874-881, 2013.
 
9) Talhouk A, McAlpine JN : New classification of endometrial cancers : the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract 3 : 14, 2016.
PubMed
10) Cancer Genome Atlas Research Network ; Kandoth C, et al : Integrated genomic characterization of endometrial carcinoma. Nature 497 : 67-73, 2013.
 
11) Talhouk A, et al : A clinically apPlicable molecular-based classification for endometrial cancers. Br J Cancer 113 : 299-310, 2015.
PubMed
12) Stelloo E, et al : Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res 22 : 4215-4224, 2016.
PubMed
13) Bendifallah S, et al : Predictive Modeling : A New Paradigm for Managing Endometrial Cancer. Ann Surg Oncol 23 : 975-988, 2016.
PubMed
14) Gibson WJ, et al : The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet 48 : 848-855, 2016.
PubMed
P.240 掲載の参考文献
1) Kurman RJ, et al : Molecular pathogenesis and extraovarian origin of epithelial ovarian cancershifting the paradigm. Hum Pathol 42 : 918-931, 2011.
PubMed
2) Shigeta S, et al : Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1 : the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer. Oncogene 35 : 3577-3586, 2016.
PubMed
3) Sekine M, et al : Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families : two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res 7 : 3144-3150, 2001.
PubMed
4) Sekine M, et al : Increased incidence of brain metastases in BRCA1-related ovarian cancers. J Obstet Gynaecol Res 39 : 292-296, 2013.
PubMed
5) Patch AM, et al : Whole-genome characterization of chemoresistant ovarian cancer. Nature 521 : 489-494, 2015.
PubMed
6) Vergara D, et al : Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 291 : 59-66, 2010.
PubMed
7) Deng J, et al : Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget 7 : 55771-55788, 2016.
PubMed
8) Takai M, et a1 : The EMT (epithelial-mesenchymal-transition) -related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer. J Ovarian Res 7 : 76, 2014.
 
9) Kajiyama H, et al : Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31 : 277-283, 2007.
PubMed
10) Steg AD, et al : Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18 : 869-881, 2012.
PubMed
11) Edmond V, et al : Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility. Oncogene 34 : 996-1005, 2015.
PubMed
12) Kitatani K, et al : Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer : potential of ceramide as a metastasis-suppressor lipid. Oncogene 35 : 2801-2812, 2016.
 
13) Nakamura K, et al : Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Mol Cancer Res 15 : 78-92, 2017.
PubMed
14) Yokoi A, et a1 : Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Nat Commun 8 : 14470, 2017.
 
15) Yue P, et al : Hyperactive EGF receptor, Jaks and Stat3 signaling Promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 31 : 2309-2322, 2012.
PubMed
P.244 掲載の参考文献
1) Cristofanilli M, et al : Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351 : 781-791, 2004.
PubMed
2) Hayes DF, et al : Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12 : 4218-4224, 2006.
PubMed
3) Smerage JB, et al : Circulating tumor cells and response to chemotherapy in metastatic breast cancer : SWOG S0500. J Clin Oncol 32 : 3483-3489, 2014.
PubMed
4) Lv Q, et al : Prognostic value of circulating tumor cells in metastatic breast cancer : asystemic review and meta-analysis. Clin Transl Oncol 18 : 322-330, 2016.
 
5) Lucci A, et al : Circulating tumour cells in non-metastatic breast cancer : aprospective study. Lancet Oncol 13 : 688-695, 2012.
 
6) Rack B, et al : Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 106 (5) : pii : dju066, 2014.
 
7) Janni WJ, et al : Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clin Cancer Res 22 : 2583-2593, 2016.
PubMed
8) Yu M, et al : Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339 : 580-584, 2013.
PubMed
9) Liedtke C, et al : Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20 : 1953-1958, 2009.
PubMed
10) 日本乳癌学会 (編) : 科学的根拠に基づく乳癌診療ガイドライン 治療編, 金原出版, 2015.
 
11) Fehm T, et al : Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 9 : R74, 2007.
PubMed
12) Pestrin M, et al : Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 118 : 523-530, 2009.
PubMed
13) Paoletti C, et al : Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res 21 : 2487-2498, 2015.
PubMed
14) Lee JS, et al : Circulating tumor cells in breast cancer : applications in personalized medicine. Breast Cancer Res Treat 160 : 411-424, 2016.
PubMed
P.251 掲載の参考文献
1) Curtin JA, et al : Distinct sets of genetic alterations in melanoma. N Engl J Med 353 : 2135-2147, 2005.
PubMed
2) Cancer Genome Atlas Network : Genomic Classification of Cutaneous Melanoma. Cell 161 : 1681-1696, 2015.
PubMed
3) Hugo W, et al : Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165 : 35-44, 2016.
PubMed
4) Sakaizawa K, et al : Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. J Dermatol Sci 80 : 33-37, 2015.
PubMed
5) Woodman SE, Davies MA : Targeting KIT in melanoma : a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80 : 568-574, 2010.
PubMed
6) Adler NR, et al : Metastatic pathways in patients with cutaneous melanoma. Pigment Cell Melanoma Res 30 : 13-27, 2017.
PubMed
7) Wang JX, et al : Crosstalk in skin : melanocytes, keratinocytes, stem cells, and melanoma. J Cell Commun Signal 10 : 191-196, 2016.
PubMed
8) Kuphal S, Bosserhoff AK : E-cadherin cell-cell communication in melanogenesis and during development of malignant melanoma. Arch Biochem Biophys 524 : 43-47, 2012.
PubMed
9) Siret C, et al : Interplay between cadherins and α2β1 integrin differentially regulates melanoma cell invasion. Br J Cancer 113 : 1445-1453, 2015.
 
10) Boyd SC, et al : Oncogenic B-RAF (V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. J Invest Dermatol 133 : 1269-1277, 2013.
 
11) Richard G, et al : ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med 8 : 1143-1161, 2016.
PubMed
12) Zhai L, et al : Molecular Pathways : Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res 21 : 5427-5433, 2015.
PubMed
13) Meier F, et al : Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 147 : 62-70, 2002.
PubMed
14) Morton DL, et al : Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370 : 599-609, 2014.
PubMed
15) 高田実 : メラノーマは手術で治せるか? 再考. 日本皮膚科学会雑誌 126 : 427-432, 2016.
 
P.256 掲載の参考文献
1) Louis DN, et al : The 2016 World Health Organization Classification of Tumors of the Central Nervous System : a summary. Acta Neuropathol 131 : 803-8202016.
PubMed
2) Yan H, et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009.
PubMed
3) Suzuki H, et al : Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47 : 458-468, 2015.
PubMed
4) Noushmehr H, et al : Identlfication of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 : 510-522, 201α
 
5) Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008.
 
6) Brennan CW, et al : The somatic genomic landscape of glioblastoma Cell 155 : 462-477, 2013.
PubMed
7) Eckel-Passow JE et al : Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 372 : 2499-2508, 2015.
PubMed
8) Singh D, et al : Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337 : 1231-1235, 2012.
PubMed
9) Johnson BE, et al : Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343 : 189-193, 2014.
PubMed
10) Le DT, et al : PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372 : 2509-2520, 2015.
PubMed
11) Kim J, et al : Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell 28 : 318-328, 2015.
PubMed
12) Lee JK, et al : Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet 49 : 594-599, 2017.
PubMed
13) Jones DT, et al : Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45 : 927-932, 2013.
PubMed
14) Sturm D, et al : Hotspot mutations in H3F3A and IDHI define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22 : 425-437, 2012.
 
15) Chan KM, et al : The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27 : 985-990, 2013.
PubMed

IV がん転移の臨床 ( 研究 )

P.270 掲載の参考文献
1) Takahara T, et al : Diffusion weighted whole body imaging with background body signal suppression (DWIBS) : technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22 : 275-282. 2004.
PubMed
2) Koh DM, et al : Whole-body diffusion-weighted MRI : tips, tricks, and pitfalls. AJR Am J Roentgenol 199 : 252-262, 2012.
PubMed
3) Barajas RF Jr. Cha S : Imaging diagnosis of brain metastasis. Prog Neurol Surg 25 : 55-73, 2012.
PubMed
4) Fink KR, Fink JR : Imaging of brain metastases. Surg Neurol Int 4 : S209-219, 2013.
PubMed
5) Nagai A, et al : Increases in the number of brain metastases detected at frame-fixed, thin-slice MRI for gamma knife surgery planning. Neuro-oncology 12 : 1187-119. 2, 2010.
PubMed
6) Yuh WT, et al : Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 15 : 1037-1051, 1994.
PubMed
7) Seo JB, et al : Atypical pulmonary metastases : spectruln of radiologic findings. Radiographics 21 : 403-417, 2001.
PubMed
8) Sica GT, et al : CT and MR imaging of hepatic metastases. AJR Am J Roentgenol 174 : 691-698, 2000.
 
9) Chen L, et al : Meta-analysis of gadoxetic acid disodium (Gd-EOB-DTPA) -enhanced magnetic resonance imaging for the detection of liver metastases. PLoS One 7 : e48681, 2012.
PubMed
10) Kim HJ, et al : Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT : aprospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques. Radiology 274 : 712-722, 2015.
 
11) O'Sullivan GJ, et al : Imaging of bone metastasis : An update. World J Radiol 7 : 202-211, 2015.
 
12) Talbot JN, et al : Diagnosis of bone metastasis : recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging 55 : 374-410, 2011.
PubMed
13) Yamaguchi T : Intertrabecular vertebral metastases : metastases only detectable on MR imaging. Semin Musculoskelet Radiol 5 : 171-175, 2001.
PubMed
14) Bayanati H, et al : Quantitative CT texture and shape analysis : can it differentiate benign and malignant mediastinal lymph nodes in patients with primary lung cancer? Eur Radiol 25 : 480-487, 2015.
PubMed
15) Patel CM, et al : CT, MRI and PET imaging in peritoneal malignancy. Cancer Imaging 11 : 123-139, 2011.
PubMed
16) Helm EJ, et al : Imaging of the pleura. J Magn Reson Imaging 32 : 1275-1286, 2010.
PubMed
17) Satoh Y, et a1 : Diagnosis of peritoneal dissemination : comparison of 18F-FDG PET/CT, diffusionweighted MRI, and contrast-enhanced MDCT. AJR Am J Roentgenol 196 : 447-453, 2011.
 
18) Galassi W, et al : Intracranial meningeal disease : comparison of contrast-enhanced MR imaging with fluid-attenuated inversion recovery and fat-supPressed T1-weighted sequences. AJNR Am J Neuroradiol 26 : 553-559, 2005.
PubMed
19) Koyama T, et al : Secondary ovarian tumors : spectrum of CT and MR features with pathologic correlation. Abdom Imaging 32 : 784-795, 2007.
 
20) Lam KY, Lo CY : Metastatic tumours of the adrenal glands : a30-year experience in a teaching hospital. Clin Endocrinol (Oxf) 56 : 95-101, 2002.
 
P.275 掲載の参考文献
1) 日本アイソトープ協会 : 第7回全国核医学診療実態調査報告書. Radioisotopes 62 (8) : 545-608, 2013,
 
2) 日本核医学会 : FDG PET. PET/CT診療ガイドライン 2012. [http://www.jsnm.org/files/pdf/guideline/2012/fdgpet_guideline2012_120912.pdf] (2017年9月閲覧)
 
3) Hanaoka K, et al : FBPA PET in boron neutron capture therapy for cancer : prediction of (10) B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res 4 : 70, 2014.
 
4) Watabe T, et al : 18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1) : a comparisoln study with 18F-FDG and 11C-Methionine PET. Eur J Nucl Med Mol Imaging 44 : 321-331, 2017.
PubMed
5) Shimosegawa E, et al : Assessment of (10) B concentration in boron neutron capture therapy : potential of image-guided therapy using (18) FBPA PET. Ann Nucl Med 30 : 749-755, 2016.
PubMed
P.281 掲載の参考文献
1) Baccelli I, et al : Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31 : 539-544, 2013.
 
2) Kogita A, et al : Inter-and intra-tumor profiling of multi-regional colon cancer and metastasis. Biochem Biophys Res Commun 458 : 52-56, 2015.
PubMed
3) Suda K, et al : Small cell lung cancer transformation and T790M mutation : complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Sci Rep 5 : 14447, 2015.
PubMed
4) Navin N, et al : Tumour evolution inferred by single-cell sequencing. Nature 472 : 90-94, 2011.
PubMed
5) Naxerova K, Jain RK : Using tumour phylogenetics to identify the roots of metastasis in humans. Nat Rev Clin Oncol 12 : 258-272, 2015.
PubMed
6) Sakai K, et al : Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. Cancer Lett 405 : 22-28, 2017.
PubMed
7) Kurahashi I, et al : A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer. PLoS ONE 8 : e63249, 2013.
PubMed
P.286 掲載の参考文献
1) 国立がん研究センターがん情報サービス. がん登録・統計年次推移. [http://ganjoho.jp/reg_stat/statistics/stat/annuaLhtml] (2017年10月閲覧)
 
2) がん診療ガイドライン. [http://www.jsco-cpg.jp/top.html] (2017年10月閲覧)
 
3) Schwartz GJ, et al : Salvage treatment for recurrent squamous cell carcinoma of the oral cavity. Head Neck 22 : 34-41, 2000.
PubMed
4) Colevas AD : Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck, J Clin Oncol 24 : 2644-2652, 2006.
 
5) Hughes KS, et al : Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum 31 : 1-4, 1988.
PubMed
6) 大腸癌研究会 (編) : 大腸癌治療ガイドライン医師用 2014年版, p22, 金原出版. 2014.
 
7) Wong SL, et al : American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28 : 493-508, 2010.
 
8) Antoniou A, et al : Meta-analysis of clinical outcome after first and second liver resection for colorectal metastases. Surgery 141 : 9-18, 2007.
PubMed
9) Adam R, et al : Outcome after associating liver partition and portal vein ligation for staged hepatectomy and conventional two-stage hepatectomy for colorectal liver metastases. Br J Surg 103 : 1521-1529, 2016.
PubMed
10) Gonzalez M, et al : Risk factors for survival after lung metastasectomy in colorectal cancer patients : a systematic review and meta-analysis. Ann Surg Oncol 20 : 572-579, 2013.
PubMed
11) 日本胃癌学会 (編) : 胃癌治療ガイドライン医師用 2014年5月改訂 (第4版), 金原出版, 2014.
 
12) 日本乳癌学会 (編) : 科学的根拠に基づく乳癌診療ガイドライン 1 疫学・診断編 2015年版 (第3版). 金原出版, 2015.
 
13) NCCNガイドライン : Nccn Guidelines versionl 2018, basal cell skin cancer [https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf] (2017年10月閲覧)
 
14) NCCNガイドライン : Nccn Guidelines versionl 2017, Melanoma [https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf] (2017年10月閲覧)
 
15) Karakousis CP, et al : Metastasectomy in malignant melanoma. Surgery 115 : 295-302, 1994.
PubMed
16) 西澤綾, ほか : 悪性黒色腫の肺転移に対する外科療法の有用性. 日本皮膚科学会雑誌 116 : 1187-1193, 2006.
 
17) McDougal WS, et al : Long-term followup of patients with renal cell carcinoma treated with radio frequency ablation with curative intent. J Urol 174 : 61-63, 2005.
PubMed
18) Althausen P, et al : Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer 80 : 1103-1109, 1997.
PubMed
19) Reddy S, Wolfgang CL : The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol 10 : 287-293, 2009.
 
20) Bristow RE, et al : Cytoreductive surgery for recurrent ovarian cancer : ameta-analysis. Gynecol Oncol 112 : 265-274, 2009.
 
21) Baba Y, et al : Radiofrequency ablation for pulmonary metastases from esophageal squamous cell carcinoma. Dis Esophagus 27 : 36-41, 2014.
PubMed
P.293 掲載の参考文献
1) Nagata Y, et al : Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer : Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys 93 : 989-996, 2015,
 
2) Timmerman R, et al : Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303 : 1070-1076, 2010.
PubMed
3) Timmerman R et al : RTOG 0618 : Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients. J Clin Oncol 31 (SuppD : abstr 7523, 2013.
 
4) Zelefsky MJ, et al : High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 : 876-881, 2001.
PubMed
5) Nutting CM, et al : Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT) : a phase 3 multicentre randomised controlled triaL Lancet Oncol 12 : 127-136, 2011.
PubMed
P.299 掲載の参考文献
1) 石岡千加史 : 最新のがん薬物療法の特徴と適応 特集最新がん薬物療法. Modern Physician 33 : 277-279, 2013.
 
2) Takahashi M, et al : The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients : A retrospective, single institutional study. PLoS ONE 12 : e0179694, 2017.
PubMed
3) Eisenhauer EA, et al : New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). Eur J Cancer 45 : 228-247, 2009.
PubMed
4) 固形がんの治療効果判定のための新ガイドライン (RECISTガイドライン) 改訂版version 1. 1-日本語訳JCOG版. [http://www.jcog.jp/doctor/tool/recistv11.html] (2017年9月閲覧)
 
5) がん免疫療法開発のガイダンス 2016後期臨床試験の考え方 (案), 厚生労働省医薬品等審査迅速化事業費補助金, 革新的医薬品・医療機器・再生医療等製品実用化促進事業, ガイダンス作成のための検討委員会, 後期臨床試験ガイダンス作成ワーキンググループ.
 
6) Bohnsack O, et al : Adaptaion of the immune related response criteria : irRECIST. Ann Oncol 25 (Supplement 4) : 361-372, 2014.
 
7) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40] (2017年9月閲覧)
 
8) 有害事象共通用語規準 v4.0 日本語訳JCOG版. [http://www.jcog.jp/doctor/tool/ctcaev4.html] (2017年9月閲覧)
 
9) 日本癌治療学会 : がん診療ガイドラインの公開. [http://www.jsco-cpg.jp/] (2017年9月閲覧)
 
10) NCCNガイドライン. [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp] (2017年9月閲覧)
 
11) ASCOガイドライン. [http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/Clinical+Practice+Guidelines] (2017年9月閲覧)
 
12) 臨床試験実施ガイドライン-第III相試験を中心として-第2版 (日本癌治療学会編), 金原出版, 2008.
 
P.304 掲載の参考文献
1) Temel JS, et al : Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363 : 733-742, 2010.
PubMed
2) 宮下光令, ほか : 遺族によるホスピス・緩和ケアの質の評価に関する研究 3 (J-HOPE 3). 日本ホスピス・緩和ケア研究振興財団, 2014.
 
3) がん対策推進協議会 : 緩和ケア専門委員会報告書～今後の緩和ケアのあり方について～. 厚生労働省, 2011.
 
4) 「がんの社会学」に関する研究グループ : 2013がん体験者の悩みや負担等に関する実態調査報告書がんと向き合った4,054人の声. 静岡県立静岡がんセンター研究所, 2016.
 
5) Drinka TJ : Interdisciplinary geriatric teams : approaches to conflict as indicators of potential to model teamwork. Educational Gerontology 20 : 87-103, 1994.
 
6) Mickan S, Roger S : Characteristics of effective teams : a literature review. Aust Health Rev 23 : 201-208, 2000.
 
7) Lemieux-Charles L, McGuire WL : What do we know about health care team effectiveness? A review of the literature. Med Care Res Rev 63 : 263-300, 2006.
PubMed
8) WHO Technical Report Series No. 804 : Cancer Pain Relief and Palliative Care, World Health Organization, Geneva, 2002.
 
9) Radbruch L, Payne S : White Paper on standards and norms for hospice and palliative care in Europe : Part 1. Eur J palliat Care 16 : 278-289, 2009.
 
10) Ferrell BR, et al : Integration of Palliative Care Into Standard Oncology Care : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 35 : 96-112, 2017.
 
11) Hui D, et al : Integration of oncology and palliative care : a systematic review. Oncologist 20 : 77-83, 2015.
PubMed
12) Reyna YZ, et al : Ethical and practlcal issues in designing and conducting clinical trials in palliative care. In : Research Methods in Palliative Care, p27-41, Oxford University Press, Oxford, 2007.
 
13) MacDonald N, Weijer C : Ethical issues in palliative care research. In : Oxford Text book of Palliative Medicine, Vol 3, p76-83, 0xford University Press, Oxford, 2004.
 
14) Muncie HL, et al : Proxies' decisions about clinical research participation for their charges. J Am Geriatr Soc 45 : 929-933, 1997.
PubMed
15) Rees E, Hardy J : Novel consent process for research in dying Patients unable to give consent. BMJ 327 : 198, 2003.
PubMed

書評

最近チェックした商品履歴

Loading...